本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Effective November 1, 2024, Markus Fischer, currently Executive Vice President Operations, has been appointed to the Rohde & Schwarz Executive Board. As Chief Operating Officer (COO), he will collaborate with Christian Leicher (CEO) and Andreas Pauly (CTO) to continue to keep the company on course for growth in these challenging times. MUNICH, Nov. 21, 2024 /PRNewswire/ -- With Markus Fischer (44), Rohde & Schwarz has once again bolstered its top management team from within the company's own ranks. He joined the technology group in 2011 as Head of Corporate Material Sourcing at Munich headquarters. After another management role at Rohde & Schwarz Messgerätebau GmbH in Memmingen, he assumed overall responsibility for the group's supply chain in 2017. In July 2020, he was appointed Executive Vice President Operations, becoming a member of Corporate Management. In that role, Fischer was responsible for all Rohde & Schwarz production activities as well as the supply chain and procurement. The technology group's five production plants have a high degree of vertical integration. As Executive Vice President Operations, Fischer focused above all on improving such key aspects as efficiency, flexibility and scalability. Consequently, his division not only ensured delivery capability in times of uncertain supply chains, but also contributed substantially to the stability of Rohde & Schwarz. For Christian Leicher, President and Chief Executive Officer (CEO), the appointment of Markus Fischer as the new President and COO is the right step: "Since we have been operating for several years in an environment that poses major economic and geopolitical challenges, it is essential that we sharpen our focus on stability and scalability. This is what Markus Fischer stands for. Together, we will make the company even more resilient against external factors." Markus Fischer appreciates the trust shown in him: "In the past few years, I've been able to familiarize myself with all aspects of the company as well as its solutions and customers. I'm convinced that we need a customer-centric focus in everything we do. That will remain my guiding principle in my new position. I'm looking forward to working with my Executive Board colleagues and the employees to ensure the company's ongoing growth." As Chief Operating Officer, Markus Fischer will be responsible for most of the operative business of Rohde & Schwarz. Andreas Pauly, who joined the Executive Board as Chief Technology Officer in October 2023, will retain his primary responsibility for innovation, research and development. Managing Partner Christian Leicher will continue to head the Executive Board as President and CEO. Headquarters: Katrin Wehle (phone: +49 89 4129 11378; email: press@rohde-schwarz.com)
LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international collaboration. "Putting patients first" is the underlying principle driving progress in the pharmaceutical industry and the inspiration behind this year's forum. "All our efforts in creating this platform for open dialogue and international collaboration in the CGT industry ultimately aim to address patient needs," said Jesse Chen, VP of Government Affairs and Corporate Communications at GenScript, in a pre-event interview. The forum brought together global thought leaders from academia, industry, and investment sectors in CGT to explore the theme "Unlock the Full Potential of Cell and Gene Therapies." Discussions focused on the latest breakthroughs, technological innovations, and future trends, offering multi-dimensional perspectives on advancing the CGT industry to benefit more patients. The forum was moderated by Dr. Shawn Wu, President of European Division at GenScript. Sherry Shao, Rotating CEO of GenScript, delivered the opening remarks, emphasizing: "Every step forward in CGT, every innovation, is ultimately about serving patients better." She reaffirmed GenScript's commitment to driving innovation in CGT and collaborating with global partners to bring life-changing therapies to more patients worldwide. The forum featured two keynote sessions with distinguished speakers: Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics, and Dr. James Wilson, a pioneer in gene therapy and President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs. Their thought-provoking presentations not only deepened attendees' understanding of the field but also offered valuable insights into the future of cell and gene therapy (CGT). Dr. Forte's delivered a keynote titled "Status and Expectations for Cell and Gene Therapy in 2024 and Beyond," focused on the transformative potential of cell therapy. He delved into gene editing, in vivo therapies, and the challenges and opportunities associated with regulatory approval. He emphasized the importance of understanding the long-term nature of cell therapy development and the significance of global collaboration. Dr. Wilson's keynote, "The Case for Rare Diseases in Genetic Medicine Development," He emphasized the importance of gene therapy for rare diseases and elaborated on the commercialization challenges of gene therapy products and discussed issues encountered in clinical development, such as technological shortcomings, the complexity of clinical trials, and production challenges. Dr. Wilson also emphasized the importance of patient advocacy and social media in promoting drug accessibility and raising public awareness. Additionally, he highlighted the need to focus on reimbursement mechanisms and achieve a balance between innovation and the resource utilization of health authorities. In addition to the compelling keynote speeches, the forum featured a range of dynamic interactive sessions, including three roundtable discussions and a fireside chat. These sessions attracted significant attention, offering lively debates and actionable insights that resonated with the audience. The success of CAR-T therapies in hematologic malignancies has revealed the vast potential of cell therapies. Now, the focus is on extending these breakthroughs to broader patient populations, including those with solid tumors and autoimmune diseases, which have become a shared goal across the industry. During the "Technology Innovation and Breakthroughs in Cell Therapy" roundtable, Mr. Stephen Hansen, Director of Biopharma Intelligence at BioCentury, moderated a vibrant discussion featuring leaders such as Dr. Ying Huang, CEO of Legend Biotech, Dr. Reagan Jarvis, CEO and Co-founder of Anocca, Dr. Pascal Touchon, Chairman of the Board at Atara Biotherapeutics, Mr. Jason Foster, CEO and Executive Director of Ori Biotech, and Dr. Biao Zheng, CEO of BRL Medicine. They approached the topic from the patient's perspective, highlighting the exceptional efficacy of CAR-T therapy. The experts also shared promising clinical data on the use of CAR-T drugs for autoimmune diseases and expressed high hopes for their future development. They emphasized that developing more patient-friendly, user-friendly CAR-T therapies is critical for increasing patient acceptance. Additionally, expanding production capacity, improving product accessibility, and ensuring product safety are urgent priorities. Collaboration with medical centers is key to developing commercially viable products. As innovative therapies continue to be researched, the potential applications of CAR-T therapy will be further unlocked, offering patients more treatment options. Driven by technological breakthroughs, significant progress has been made in gene therapy and mRNA vaccine fields, with applications expanding rapidly. However, the production of these therapies is complex, particularly when it comes to the choice, production, and optimization of delivery vectors, which have a profound impact on their development. In the roundtable discussion on "Progress in Gene Therapy and mRNA Vaccine," hosted by Ms. Kristina Cornish, Partner at Pinsent Masons, London & European and UK Patent Attorney, leading researchers including Mr. Deividas Pazeraitis, Senior Scientist at AstraZeneca, Dr. Karim Benabdellah, Principal Investigator at GENYO, Dr. Maelle Quere, Scientist at Sanofi, Dr. Vincenzo Di Cerbo, Lead Technical Scientist at Cell and Gene Therapy Catapult, and Dr. Lumeng Ye, Director of Novel therapeutic materials at GenScript; all agreed that long-term delivery efficiency and technological bottlenecks remain key challenges in translating innovations into clinical applications. The discussion focused on the technological trends and innovative developments in the clinical applications of gene editing, the topics cover the selection of viral vectors (VP), non-viral vectors (NVP), lipid nanoparticles (LNP), and virus-like particles (VLP) in different application areas, the innovative developments in gene therapy and mRNA vaccines, as well as an analysis of the advantages and disadvantages of mRNA vaccines compared to traditional vaccines, along with development trends and application prospects. They also provided a comprehensive review of the progress from technological innovation to clinical application in this field and unanimously agreed that long-term delivery technology and in vitro cell line technology remain key challenges. The development process for CGT is highly complex and personalized, and these characteristics are seen as major challenges to the continuous supply of these therapies. In the subsequent roundtable discussion on "CMC Challenges with Developing & Manufacturing Cell and Gene Therapies," led by Dr. Qingyu Cao, Senior Director & head of European Business Development at ProBio, and panelists are Dr. Jim Faulkner, CEO of JDB BioConsulting, Mr. Arindam Mitra, CMC Director at Leucid Bio, Dr. Dima Al-hadithi, Director at Minaret Consulting Limited, and Ms. Ming Ewe, CEO of Smarter Biotech Solutions, engaged in lively discussions on key issues such as production process standardization, quality control, and viral vector production. The discussion presented practical strategies and solutions, providing important references for the widespread application of CGT. The experts emphasized the need for early planning of CMC and regulatory strategies in the context of accelerated approval processes, ensuring that product development and quality control can proceed in parallel. They also highlighted the importance of selecting the right CDMO partners to support full collaboration. Furthermore, they suggested that efforts should begin early in the R&D phase, with active communication with regulatory agencies to enhance the understanding of new technologies and methods, and a clear supply chain map should be created to ensure stable supply. Regarding future trends, the experts believe that AI technology will play a key role in optimizing gene therapy design, improving production efficiency, and advancing automation processes. They are confident that, with ongoing technological advancements and increasing market competition, the price of CGT therapies will gradually decrease, making them a widely accessible treatment option. R&D and manufacturing in the cell and gene therapy field require substantial financial investment, with long return cycles, making funding pressure a key constraint on industry growth. In the closing fireside chat, "Navigating the Future of CGT: Insights from Investors," was moderated by Dr. Kelly Shi, Senior VP & Research Analys at Jefferies LLC, Dr. Josh Resnick, Senior Managing Director at RA Capital Management, and Mr. Ping Shek, Managing Director at Stifel's Investment Banking Division, discussed the investment landscape for CGT. The speakers shared their investment insights in the CGT field, reviewing the evolution of the sector from its early boom to the current adjustment phase. When discussing investment strategies, the participants highlighted key considerations such as addressing patient needs, reducing uncertainty in research and development as well as manufacturing, and increasing commercialization success rates. They also emphasized the need for continued innovation in reducing manufacturing costs. Regarding the investment trend in CGT, despite market fluctuations, signs of recovery began to emerge in 2023, indicating a positive outlook for future capital inflows. Currently, investment behavior is becoming more cautious, and the market is steadily moving toward normalization. Furthermore, the evolving regulatory environment and changes in reimbursement policies have had a profound impact on investment decisions. Addressing infrastructure development and therapy accessibility is viewed as a core driver for the sustained growth of the industry. The GenScript Biotech Global Forum concluded successfully with engaging discussions from experts and scholars. This event brought together global leaders from the biopharmaceutical industry, who shared valuable experiences and unique insights, injecting fresh momentum into the continued development and innovation of the global cell and gene therapy sector. Moving forward, GenScript Biotech remains committed to building more open and inclusive collaboration platforms to drive innovation and progress in the field of cell and gene therapy. As an annual event, the GenScript Global Forum will continue to uphold its core focus of "patient-centered" goals, advancing scientific innovation and market applications in cell and gene therapies, bringing greater hope for a healthier global future. About GenScript Biotech Corporation GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website https://www.genscript.com
HONG KONG, Nov. 21, 2024 /PRNewswire/ -- Bwine, a brand synonymous with strength, heroism, and innovation, is excited to announce the launch of the F7MINI SE drone, just in time for Black Friday/Cyber Monday-two of the busiest days in the retail calendar. Available now on Amazon, this cutting-edge drone is set to redefine aerial photography and videography with its advanced features and unbeatable promotional pricing. Bwine F7MINI SE drone - Ideal for Beginners and Aerial Photography The F7MINI SE: A Leap Forward in Drone Technology The F7MINI SE offers significant improvements over its predecessor F7MINI, including digital image transmission for better connectivity and image quality, increased flight time, and reduced weight for greater portability. These enhancements are a testament to Bwine's commitment to pushing the boundaries of possibility Weighing in at just 238 g, this lightweight drone does not require FAA registration, making it accessible for enthusiasts and professionals alike. Its digital image transmission system allows for quick and seamless connection to smartphones, ensuring users can capture stunning visuals with ease. With an impressive transmission and flight range of 9,842 feet (3,000 meters), the F7MINI SE enables breathtaking long-distance shots. The drone is equipped with GPS positioning, TOF positioning, optical flow positioning, and barometric altitude hold, with the newly added TOF positioning ensuring smoother low-altitude flights and landings. The F7MINI SE also comes with two batteries, offering a total flight time of 70 minutes, allowing users to explore and capture more without frequent recharging. Its GPS auto-return feature, including one-key return, low battery return, and signal loss return, provides peace of mind during flights. Additionally, the drone boasts a variety of functions such as image follow, GPS follow, orbit flight, waypoint flight, and gesture photo and video capture, making it a versatile tool for creative exploration. Get ready to make some great saving In celebration of the Black Friday/Cyber Monday Event, Bwine is offering the F7MINI SE for a special price. Originally priced at $349.98, the F7MINI SE is now available for just $237.98, an unprecedented 32% discount. For those looking to enhance their F7MINI SE experience, Bwine recommends pairing the drone with a white 65W charging head, ensuring quick and efficient charging for uninterrupted adventures. Bwine continues to stand as a symbol of power, resilience, and courage, empowering individuals to embrace challenges and explore new horizons. More than just a brand, Bwine is a symbol of the heroic spirit, dedicated to empowering those who dare to lead, fight, and forge their own path. As a trusted ally, Bwine is committed to standing by the side of every hero on their journey, inspiring them to unlock their full potential. For more information, please visit https://www.bwine.net/ Media Contactpr@rukotoy.com
Augmentir's exceptional performance and contributions in the global ACW solutions space highlight its dedication to sustained innovations and higher customer value. SAN ANTONIO, Nov. 21, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the augmented connected worker (ACW) industry and, based on its findings, recognizes Augmentir with the 2024 Global Company of the Year Award. David Pressman, Senior Underwriter, Marine Cargo at Markel Offering a world-class artificial intelligence (AI)-powered ACW solution, Augmentir enables industrial companies to enhance their frontline workforce's safety, quality, and efficiency. Augmentir illustrates remarkable agility and addresses unmet customer needs by developing purpose-driven products that deliver tangible outcomes and constantly evolve alongside the market. This adaptability enables it to set higher performance and innovation benchmarks, raising the bar for existing and new market players. Augmentir has a broad global customer base, with successful product deployments in over 75 countries, demonstrating a far-reaching impact. This notable base exhibits the company's product excellence and entails many prominent names, including Colgate-Palmolive, Mondelēz International, Armstrong World Industries, Hitachi Energy, and Müller Group. Augmentir's upward momentum in a highly competitive global market demonstrates its unsurpassed capacity to continuously and quickly create solutions that exceed industry expectations. Augmentir is created by the same visionary experts behind multiple software technology revolutions (Wonderware Software, Lighthammer, and ThingWorx), indicating the company's unmatched technological and market knowledge. Augie™, Augmentir's GenAI Suite of AI services and assistants for industrial frontline work is a solid example of the company's incomparable emphasis on continuous innovations, differentiating itself from competing products with broad applicability, efficiency-driven features, and unmatched customer benefits. Agustin Fabris, research analyst for Industrial Automation & Software at Frost & Sullivan, observed, "Augmentir offers one of the most comprehensive ACW platforms on the market. Its diverse customer base, outstanding growth rates, advanced AI and skills management capabilities, and innovative product roadmap will ensure that the company maintains its leadership position for years to come." Augmentir's holistic technology platform surpasses competitors by helping customers digitize skills and training, work instructions, checklists, and standard operating procedures while curating transformative digital workflows and integrations that unite frontline workers with their business' digital threads. The company's ability to quickly tackle changing trends with problem-driven solutions is remarkable, showcasing unsurpassed adaptability and market readiness. As a growth-centric company, Augmentir proactively explores new opportunities, product development and upgrades, partnerships, and customer acquisitions, exponentially magnifying its business infrastructure. Since Augmentir platform's inception, the company has been at the forefront of AI innovation in the ACW sector. Augmentir's value-driven, outcome-oriented, and user-centric best practices translate into longstanding and nurturing stakeholder relations, further cementing its industry position as a technology and people leader. "Augmentir persistently surpasses competitors with its relentless focus on research and development, customer feedback, and ability to evolve alongside the market. Harnessing the power of GenAI and growth-driven initiatives, Augmentir well-equips itself to deliver robust customer value and benefits while achieving exponential business expansion globally," added Iqra Azam, best practices research analyst at Frost & Sullivan. Augmentir earns Frost & Sullivan's 2024 Global Company of the Year Award for its strong overall performance in the ACW industry. Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in customer value and market penetration. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Camila TinajeroP: +54911 6713 2748E: Camila.Tinajero@frost.com About Augmentir Augmentir™ is the world's only AI-Powered Connected Worker solution. Augmentir's software includes a complete suite of connected worker capabilities, connectors to business systems, and broad extensibility that enable manufacturers to digitize their frontline operations, reduce onboarding time, and increase workforce productivity. Companies in manufacturing, service, energy, and construction leverage Augmentir's suite of tools to deliver effective skills management, training, digital workflow, and collaboration for today's more dynamic industrial workforce. For more information, please visit www.augmentir.com. Photo - https://mma.prnasia.com/media2/2563448/Augmentir_Award.jpg?p=medium600
BREA, Calif., Nov. 21, 2024 /PRNewswire/ -- Just in time for the holiday season, ICECO, a leading expert in portable refrigeration solutions, is kicking off its biggest sale event of the year, with unbeatable prices on top-rated portable fridges and camping gear. From solo trips to family outings, ICECO's Black Friday & Cyber Monday Sale has everything to keep your food fresh on any adventure. Huge BFCM Savings with ICECO from November 21 to December 3. Starting today, enjoy up to 30% off select models with early access, and starting Nov. 26, exclusive deals and promotions will expand across the entire product lineup. These deals are available on the ICECO Website and the ICECO Amazon Store. Exclusive deals include: APL35 (37QT): Save $120 on this ultra-lightweight 12V fridge, built from durable all-aluminum material and equipped with the high-efficiency SECOP Nano compressor for fast, effective cooling. The lid stay function keeps the lid open at any angle above 45°, ensuring easy access and preventing accidental closures, keeping children safe while they grab a snack. APL55 (58QT): Enjoy $172 off on this versatile and stylish fridge. Designed for rugged adventures, it functions even at steep angles above 40° during off-roading. With a flexible dual-zone cooling setup and a removable divider, it offers both single and dual-zone configurations to handle all refrigeration and freezing needs. VL75ProD (79.2QT): Take $200 off and choose between classic matte black or unique olive green color. With a multi-directional lid and independent temperature control, this model keeps your food perfectly chilled or frozen without ice, no matter where the road takes you. VL60D (63.4QT): Save $212 and get a free protective cover! The only dual-zone model in ICECO's 60L lineup, this retro-green fridge prevents flavor mixing and offers ample capacity for home, car, or boat use, making it perfect for various uses. JP Series (31.7QT/42QT/52.8QT): Get unbeatable prices on this classic series, featuring top-tier SECOP compressors. Starting at just $350, the JP30, JP40 ($370), and JP50 ($390) models feature a compact, narrow design to save space and are built with durable ABS shells. With Bluetooth app control, they make cooling on the go more convenient than ever. Please note that due to rounding or system limitations, the actual discounted price may vary slightly from the savings amount mentioned above. There's more! Don't miss your chance to enjoy massive savings on ICECO camping gear. Plus, join our fun social media events to save even more and get a shot at winning an exclusive ICECO holiday gift pack! This BFCM, elevate your travel experience with ICECO's reliable, innovative refrigeration solutions designed for any journey. These exclusive deals make ICECO's high-quality fridges more accessible, letting you keep food fresh and enjoy great meals even in the wild. Discover more BFCM savings at icecofreezer.com and gear up for your next adventure! About ICECODecades of innovation have positioned ICECO as a leading expert in portable car fridges. Trusted worldwide, with over 2 million units sold in 66 countries, we're the go-to for adventurers seeking quality, design, and value. Elevate your outdoor adventure with ICECO, the ultimate overland companion. Social Media:InstagramFacebookYouTubeTikTok
Industry-Leading Brand Lowers Prices on Robot Cleaners at Amazon, Costco, and Best Buy NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Narwal, the international leader in smart home cleaning, is rolling out its best-ever Black Friday deals for the 2024 holiday season. The sale will feature its lineup of innovative robot vacuums and mops and will start on November 21, 2024. Narwal's precision cleaning, zero maintenance, and adaptive AI technology create a convenient cleaning experience. The sale can be found on the Narwal website, Amazon, Costco, and Best Buy across the United States and Canada. "The smart home robot vacuum industry is projected to be valued at over $50 billion by 2028," said Junbin Zhang, CEO of Narwal. "The technology behind new home automated cleaners has advanced tremendously, offering intelligent navigation, AI integration, customized scheduling, and adaptive suction, which provide a convenient solution for households looking to simplify cleaning routines. Narwal's Black Friday offers are a great opportunity to experience our top-tier home cleaning at a fraction of the cost." Featured Black Friday Deals Black Friday Deals are available between November 21, 2024, and December 2, 2024. Each Narwal model offers specialized features to keep floors spotless with minimal input, making them a perfect fit for today's fast-paced lifestyles. Black Friday deals will be available on the Narwal website, the brand's Amazon store, Costco, and Best Buy. Narwal Freo Z UltraOriginal Price: $1,499.99 | Black Friday Price: $1,099.99The brand's most advanced model features the world's first Dual RGB Cameras with Dual AI Chips in a robot vacuum, detecting obstacles and messes in real time while executing adaptive, ultra-quiet cleaning strategies. The Freo Z Ultra combines Narwal's most advanced technology to deliver a hands-free cleaning experience. Its self-cleaning base station with 120-day dust collection ensures virtually maintenance-free operation. The mop also has an adaptive hot water mop washing system to ensure it stays pristine and hygienic. This TÜV-certified model also prioritizes privacy, while its 12,000 Pa suction power eliminates 99% of dirt without tangling, thanks to its unique conical brush. Narwal Freo X UltraOriginal Price: $1,399.99 | Black Friday Price: $799.99The Freo X Ultra is a premium, maintenance-free robot vacuum and mop launched in March of this year. It's more affordable than flagship models yet still delivers powerful cleaning performance with minimal maintenance. It's especially suitable if consumers must clean up a lot of hair or pet fur. It offers powerful performance at Narwal's lowest price ever. It delivers 8200 Pa suction with DirtSense™ technology for efficient cleaning and obstacle avoidance – a tri-laser array monitors surroundings to avoid small and low-lying objects, and a side-laser enables the robot to clean within millimeters of them. The system's zero-tangle floating brush ensures smooth, easy, and consistent cleaning. The all-in-one base station handles self-cleaning and drying, ensuring a low-maintenance experience. Narwal FreoOriginal Price: $899.99 | Black Friday Price: $499.99Narwal Freo is a Black Friday deal you can't miss: Get this powerful robot vacuum and mop combo with an all-in-one base station for just $499.99—an unbeatable value. The brand's state-of-the-art all-in-one vacuum and mop system, featuring DirtSense™ technology, combines powerful suction with targeted cleaning. Liftable mopping pads dry carpets, enabling versatile flooring adaptation, and EdgeSwing™ for precise edge cleaning. Ideal for those seeking reliable, everyday cleaning, the budget-friendly Freo covers all bases for budget-conscious households looking for an effective, all-in-one solution. Narwal Freo X PlusOriginal Price: $399.99 | Black Friday Price: $279.99The entry-level Freo X Plus brings robust performance with its zero-tangling brush and 7,800 Pa suction, which is ideal for pet owners or anyone dealing with high foot traffic and frequent messes. The tri-laser obstacle avoidance and voice-command integration deliver precision and convenience for a home cleaning experience. The unit is equipped with dust compression technology, with self-emptying internal operation for up to 7 weeks of dust storage. Narwal S20 ProOriginal Price: $499.99 | Black Friday Price: $399.99The all-in-one cordless S20 Pro features advanced AI, powerful 20,000Pa suction with 20N down pressure, self-cleaning, and ultra-quiet performance. With DirtSense™ technology, extended battery life, and 180° flat-reach, it's built to handle heavy dirt and spills in any home. This comprehensive solution uses the upgraded tangle-free brush to tackle hard-to-reach spaces. Give the Gift of Cleaning Convenience Narwal's exclusive Black Friday deals will be available in the United States and Canada for a limited time. Shoppers are encouraged to visit the Narwal website, the brand's Amazon store, or retailers like Costco and Best Buy to take advantage of these savings. About Narwal Narwal is known for using its cutting-edge technology to realize its objective of bringing flawless floors to users. It's one of the top 5 robotic cleaning manufacturers, with the brand achieving $200 million in sales within two years of introducing its first product and maintaining high double-digit annual growth ever since. Narwal has raised substantial funds from investors, including Sequoia Capital, Hillhouse Capital, ByteDance (parent of TikTok), and Tencent, among others. With over 700 researchers and scientists from across the globe, Narwal has made numerous breakthroughs in multiple fields and won prestigious international awards, including the Edison Gold Award, which honors innovation, and Time Magazine's Best Inventions.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
